Baseline NT-Pro-BNP levels and arrhythmia recurrence in outpatients undergoing elective cardioversion of persistent atrial fibrillation: A survival analysis

Indian Pacing and Electrophysiology Journal

Volumn 9, Issue 1, 2009, Pages 15-24

  Sanna, Tommaso ^a   Sonaglioni, Andrea ^a   Pieroni, Maurizio ^a   Russo, Antonio Dello ^a   Pelargonio, Gemma ^a   Casella, Michela ^a   Zichichi, Evelina ^a   La Torre, Giuseppe ^a   Narducci, Maria Lucia ^a   Bellocci, Fulvio ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Arrhythmia recurrence; Cardioversion; NT Pro BNP; Persistent atrial fibrillation

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADULT; ARTICLE; CARDIOVERSION; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HOSPITAL DISCHARGE; HUMAN; MALE; OUTPATIENT; PATIENT REFERRAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RECURRENT DISEASE; SENSITIVITY AND SPECIFICITY; SURVIVAL; UNIVARIATE ANALYSIS;

EID: 67649989940     PISSN: None     EISSN: 09726292     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Chungh SS, Blackshear JL, Shen WK. Epidemiology and natural history of atrial fibrillation. JACC 2001; 37: 371-378.
2. Feinberg WM, Blackshear JL, Laupacis A. Prevalence, age distribution and gender of patients with atrial fibrillation: analysis and implication. Arch Intern Med 1995; 155: 469-473.
3. Dittrich HC, Erickson JS, Scneiderman T, Blacky AR, Savides T, Nicod PH. Echocardiographic and clinical predictors for outcome of elective cardioversion of atrial fibrillation. Am J Cardiol 1989; 63: 193-7.
4. Van Gelder IC, Crijns HJ, Tieleman RG, et al. Chronic atrial fibrillation. Arch Intern Med 1996; 156: 2585-92.
5. Van Gelder IC, Crijns HJ, Van Gilst WH, Verwer R, Lie KI. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol 1991; 68: 41-6.
6. Duytschaever M, Haerynck F, Tavernier R, Jordaens L. Factors influencing long-term persistence of sinus rhythm after a first electrical cardioversion for atrial fibrillation. Pacing Clin Electrophysiol 1998; 21: 284-7.
7. Brodsky MA, Allen BJ, Capparelli EV, Luckett CR, Morton R, Henry WL. Factors determining maintenance of sinus rhythm after chronic atrial fibrillation with left atrial dilatation. Am J Cardiol 1989; 63: 1065-8.
8. Alt E, Ammer R, Lehmann G, et al. Patient characteristics and underlying heart disease as predictors of recurrent atrial fibrillation after internal and external cardioversion in patients treated with oral sotalol. Am Heart J 1997; 134: 419-25.
9. Flugelman MY, Hasin Y, Katznelson N, Kriwisky M, Shefer A, Gotsman MS. Restoration and maintenance of sinus rhythm after mitral valve surgery for mitral stenosis. Am J Cardiol 1984; 54: 617-9.
10. Dogan A, Kahraman H, Ozturk M, Avsar A. P wave dispersion and left atrial appendage function for predicting recurrence after conversion of atrial fibrillation and relation of P wave dispersion to appendage function. Echocardiography 2004; 21: 523-30.
11. Kosior D, Szuic M, Piatkowski R, Rabczenko D, Torbicki A, Opolski G. Factors determining long-term maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation. Kardiol Pol 2003; 59: 128-41.
12. Palinkas A, Varga A, Nyuzo B, Gruber N, Forster T, Nemes A, Vass A. Clinical role of flow velocity of left atrial auricle for prediction of short and long term success of cardioversion in patients with non valvular atrial fibrillation. Orv Hetil 2002; 143: 2035-41.
13. Perzanowski C, Ho AT, Jacobson AK. Increased P-wave dispersion predicts recurrent atrial fibrillation after cardioversion. J Electrocardiol. 2005; 38: 43-6.
14. Ozdemir O, Soylu M, Demir AD, Alyan O, Topaloglu S. Does p-wave dispersion predict the atrial fibrillation occurrence after direct-current shock therapy? Angiology 2006; 57: 93-8.
15. Gurevitz OT, Varadachari CJ, Ammash NM, Malouf JF, Rosales AG, Herges RM, Bruce CJ, Somers VK. The effect of patient sex on recurrence of atrial fibrillation following successful direct current cardioversion. Am Heart J 2006; 152: e9-13.
16. Frick M, Fryman V, Jensen-Urstad M, Ostergren J, Rosenqvist M. Factors predicting success rate and recurrence of atrial fibrillation after first electrical cardioversion in patients with persistent atrial fibrillation. Clin Cardiol. 2001; 24: 238-44.
17. Tse HF, Lau CP, Ayers GM. Long-term outcome in patients with chronic atrial fibrillation after successful internal cardioversion. Am J Cardiol 1999; 83: 607-9.
18. Suttorp MJ, Kingma JH, Koomen EM, Van't Hof A, Tijssen JGP, Lie KI. Recurrence of paroxysmal atrial fibrillation or flutter after successful cardioversion in patients with normal left ventricular function. Am J Cardiol 1993; 71: 710-3.
19. Gosselink ATM, Crijns HJGM, Van Gelder IC, Hillege HL, Weisfield ACO, Lie KI. Low dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA 1992; 267: 3289-93.
20. Crijns HJGM, Van Gelder IC, Van Gilst WH, Hillege HL, Gosselink ATM, Lie KI. Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or flutter. Am J Cardiol 1991; 68: 335-41.
21. Chen HH, Burnett JC Jr. The natriuretic peptides in heart failure: diagnostic and herapeutic potentials. Proc Assoc Am Physycians 1999; 111: 406-16.
22. Wiese S, Breyer T, Dragu A, et al.. Gene expression of brain natriuretic peptide in isolated atrial and ventricular myocardium: influence of angiotensin II and diastolic fiber length. Circulation 2000; 102: 3074-9.
23. Clerico A, Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of the cardiac natriuretic peptides: a review. Clin Chem 2004; 50:33-50.
24. Abassi Z, Karram T, Ellaham S, Winaver J, Hoffman A. Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance. Pharmacol Ther 2004; 102: 223-41.
25. Hunt PJ, Richards AM, Nicholls MG, et al. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf). 1997; 47: 287-96.
26. Mc Cullough PA, Omland T, Maisel AS. B-type natriuretic peptides: a diagnostic breakthrough for clinicians. Rev Cardiovasc Med 2003; 4: 72-80.
27. Horie H, Tsutamoto T, Minai K, Hayashi M, Kito O, Kinoshita. Brain natriuretic peptide predicts chronic atrial fibrillation after ventricular pacing in patients with sick sinus syndrome. Jpn Circ J. 2000; 64: 965-70.
28. Wazni OM, Martin DO, Marrouche NF, Natale A. Plasma B-type natriuretic peptide levels predict postoperative atrial fibrillation in patients undergoing cardiac surgery. Circulation 2004; 110: 124-7.
29. Beck-da Silva L, de Bold A, Fraser M, Williams K, Haddad H. BNP predicts successful cardioversion in patients with atrial fibrillation and maintenance of sinus rhythm. Can J Cardiol 2004; 20: 1245-8.
30. Lellouche N, Berthier R, Mekontso-Dessap A, Braconnier F, Monin JL, Duval AM, Dubois-Randé JL, Guéret P, Garot J. Usefulness of plasma B-type natriuretic peptide in predicting recurrence of atrial fibrillation one year after external cardioversion. Am J Cardiol. 2005;95:1380-2.
31. Madrid AH, Bueno MG, Rebollo JM, Marin I, Pena G, Bernal E, Rodriguez A, Cano L, Cano JM, Cabeza P, Moro C. Use of irbesertan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation. 2002;106:331-6.